AYTU BioPharma is a pharmaceutical company focused on commercializing products that address healthcare needs. Co.'s Primary Care Portfolio includes: Natesto®, which is a nasal formulation of testosterone for men with hypogonadism (low testosterone); ZolpiMist®, which is an oral spray prescription sleep aid; and Tuzistra® XR, which is a codeine-based antitussive syrup. Co.'s Pediatric Portfolio includes; Cefaclor, which is a cephalosporin antibiotic suspension; Karbinal® ER, which is an extended-release carbinoxamine (antihistamine) suspension indicated to treat various allergic conditions; and Poly-Vi-Flor® and Tri-Vi-Flor®, which are prescription fluoride-based supplement product lines. The AYTU stock yearly return is shown above.
The yearly return on the AYTU stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AYTU annual return calculation with any dividends reinvested as applicable (on ex-dates).
|